NCT06040060

Ketamine Effects as Preemptive Analgesia

Name: Clinical Trial NCT06040060
Creator: Universitas Padjadjaran
Keywords: Pain, Postoperative, Ketamine, Phase 2/3, drug, clinical trial, Indonesia

Effects of Ketamine 0.5 Mg/Kgbw Administration as Preemptive Analgesia on Analgesia Duration and the Need for Fentanyl Following Hysterectomy Surgery

Universitas Padjadjaran·Phase 2/3·ClinicalTrials.gov·drugCompleted

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Pain, Postoperative
Drug/Device/Intervention: Ketamine
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Universitas Padjadjaran
Location: Bandung, Indonesia

Timeline & enrollment

Phase: Phase 2/3
Start date: Dec 27, 2022
End date: Mar 03, 2023
Enrollment: 40 participants

Primary outcome

Duration of postoperative analgesia,Total need for post-operative analgesic rescue

Summary

The goal of this randomized controlled trial is to compare the effect of preemptive ketamine administration to placebo administration in patients underwent hysterectomy surgery. The main questions it aims to answer are:  1. To determine the effect of ketamine at a dose of 0.5 mg/kgBW as preemptive analgesia on the duration of analgesia after hysterectomy surgery  2. To determine the effect of ketamine at a dose of 0.5 mg/kgBW as preemptive analgesia on the need for fentanyl after hysterectomy surgery

ICD-10 classifications

During surgical operationDuring surgical operationDuring surgical operationPain, unspecifiedPostoperative intestinal obstruction

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06040060
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06040060 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Universitas Padjadjaran and is currently Completed. The study focuses on Pain, Postoperative. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.